To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypercholesterolemia
Intervention: Comparator: ezetimibe/simvastatin + niacin (ER) (Drug); Comparator: Placebo to ezetimibe/simvastatin (Drug); Comparator: niacin (ER) tablet (Drug); Comparator: ezetimibe (+) simvastatin (Drug); Comparator: Placebo to Niacin (ER) (Drug); Comparator: ezetimibe/simvastatin and niacin (ER) (Drug); Comparator: ezetimibe and simvastatin (Drug); Comparator: Placebo to niacin (ER) (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Merck Sharp & Dohme Corp. Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck Sharp & Dohme Corp.
Summary
To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with
high cholesterol.
Clinical Details
Official title: Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
Secondary outcome: Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C) Percent Change From Baseline in Triglycerides (TG) Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C) Percent Change From Baseline in Triglycerides (TG) Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
Eligibility
Minimum age: 18 Years.
Maximum age: 79 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to
500 mg/dL
- Patient willing to be on a low-cholesterol diet
Exclusion Criteria:
- Pregnant or lactating women or intending to become pregnant
- Patient with sensitivity or intolerance to ezetimibe, simvastatin, or
ezetimibe/simvastatin combination tablet
- Patient with sensitivity or intolerance ro niacin, any component or niacin extended
release or aspirin
- Patient for whom discontinuation of existing lipid-lowering therapy treatment poses
an unacceptable risk
Locations and Contacts
Additional Information
Related publications: Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72. doi: 10.1016/j.jacc.2008.03.003.
Starting date: December 2005
Last updated: October 31, 2014
|
